Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center

doi:10.4251/wjgo.v16.i12.4675

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (179)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=119

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=35

Publishing Process of This Article

Item

Count

Browse

Download

Sum=15

Dec 15, 2024 (publication date) through Nov 14, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4675-4684
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4675

Open in New Tab Full Size Figure Download Figure

Figure 1 Overall survival. A: Overall survival (OS) in patients with gastroenteropancreatic neuroendocrine tumors; B: OS according to primary tumor; C: Progression-free survival based on primary tumor.

Citation: Cruz-Diaz WE, Paitan V, Medina J, Flores R, Haro-Varas J, Mantilla R, Castro-Oliden V. Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center. World J Gastrointest Oncol 2024; 16(12): 4675-4684
URL: https://www.wjgnet.com/1948-5204/full/v16/i12/4675.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i12.4675